Effects of folate and folylpolyglutamyl synthase modulation on chemosensitivity of breast cancer cells

Molecular Cancer Therapeutics

Volumn 6, Issue 11, 2007, Pages 2909-2920

  Cho, Robert C ^b   Cole, Peter D ^f   Sohn, Kyoung Jin ^a   Gaisano, Gregory ^a   Croxford, Ruth ^c   Kamen, Barton A ^e   Kim, Young In ^a,b,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; FLUOROURACIL; FOLIC ACID; FOLIC ACID ANTAGONIST; FOLINIC ACID; FOLYLPOLYGLUTAMATE SYNTHASE; METHOTREXATE; PEMETREXED; TRIMETREXATE;

ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DNA TRANSFECTION; DRUG EFFECT; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FOLIC ACID; GLUTAMATES; GUANINE; HUMANS; INHIBITORY CONCENTRATION 50; METHOTREXATE; PEPTIDE SYNTHASES; POLYGLUTAMIC ACID; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 36749094617     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0449     Document Type: Article

References (43)

1. Shane B. Folate chemistry and metabolism. In: Bailey LB, editor. Folate in health and disease. New York: Marcel Dekker; 1995. p. 1-22.
2. Kamen B. Folate and antifolate pharmacology. Semin Oncol 1997;24:S18-30-S18-39.
3. Moran RG. Roles of folylpoly-γ-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: an overview. Semin Oncol 1999;26:24-32.
4. Pizzorno G, Mini E, Coronnello M, et al. Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug. Cancer Res 1988;48:2149-55.
5. McCloskey DE, McGuire JJ, Russell CA, et al. Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J Biol Chem 1991;266:6181-7.
6. Mauritz R, Peters GJ, Priest DG, et al. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Biochem Pharmacol 2002;63:105-15.
7. Liani E, Rothem L, Bunni MA, Smith CA, Jansen G, Assaraf YG. Loss of folylpoly-γ-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer 2003;103:587-99.
8. Sanghani SP, Sanghani PC, Moran RG. Identification of three key active site residues in the C-terminal domain of human recombinant folylpoly-γ- glutamate synthetase by site-directed mutagenesis. J Biol Chem 1999;274:27018-27.
9. Zhao R, Titus S, Gao F, Moran RG, Goldman ID. Molecular analysis of murine leukemia cell lines resistant to 5,10-dideazatetrahydrofolate identifies several amino acids critical to the function of folylpolyglutamate synthetase. J Biol Chem 2000;275:26599-606.
10. Roy K, Egan MG, Sirlin S, Sirotnak FM. Posttranscriptionally mediated decreases in folylpolyglutamate synthetase gene expression in some folate analogue-resistant variants of the L1210 cell. Evidence for an altered cognate mRNA in the variants affecting the rate of de novo synthesis of the enzyme. J Biol Chem 1997;272:6903-8.
11. Kim JS, Lowe KE, Shane B. Regulation of folate and one-carbon metabolism in mammalian cells. IV. Role of folylpoly-γ-glutamate synthetase in methotrexate metabolism and cytotoxicity. J Biol Chem 1993;268:21680-5.
12. Aghi M, Kramm CM, Breakefield XO. Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo. J Natl Cancer Inst 1999;91:1233-41.
13. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8.
14. Radparvar S, Houghton PJ, Houghton JA. Effect of polyglutamylation of 5,10-methylenetetrahydrofolate on the binding of 5-fluoro-2′- deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft. Biochem Pharmacol 1989;38:335-42.
15. Romanini A, Lin JT, Niedzwiecki D, Bunni M, Priest DG, Bertino JR. Role of folylpolyglutamates in biochemical modulation of fluoropyrimidines by leucovorin. Cancer Res 1991;51:789-93.
16. Wang FS, Aschele C, Sobrero A, Chang YM, Bertino JR. Decreased folylpolyglutamate synthetase expression: a novel mechanism of fluorouracil resistance. Cancer Res 1993;53:3677-80.
17. Cheradame S, Etienne MC, Chazal M, et al. Relevance of tumoral folylpolyglutamate synthetase and reduced folates for optimal 5-fluorouracil efficacy: experimental data. Eur J Cancer 1997;33:950-9.
18. Sohn KJ, Smirnakis F, Moskovitz DN, et al. Effects of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate. Gut 2004;53:1825-31.
19. Backus HH, Pinedo HM, Wouters D, et al. Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates. Int J Cancer 2000;87:771-8.
20. Zhao R, Gao F, Goldman ID. Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. Biochem Pharmacol 2001;61:857-65.
21. Garrow TA, Admon A, Shane B. Expression cloning of a human cDNA encoding folylpoly(γ-glutamate) synthetase and determination of its primary structure. Proc Natl Acad Sci U S A 1992;89:9151-5.
22. McGuire JJ, Russell CA. Folylpolyglutamate synthetase expression in antifolate-sensitive and -resistant human cell lines. Oncol Res 1998;10:193-200.
23. Cole PD, Kamen BA, Gorlick R, et al. Effects of overexpression of γ-glutamyl hydrolase on methotrexate metabolism and resistance. Cancer Res 2001;61:4599-604.
24. Panetta JC, Wall A, Pui CH, Relling MV, Evans WE. Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of γ-glutamyl hydrolase activity. Clin Cancer Res 2002;8:2423-9.
25. Tamura T. Microbiologicl assay of folate. In: Picciano MF, Stokstad ELR, Gregory III JF, editors. Folic acid metabolism in health and disease. New York: Wiley-Liss; 1990. p. 121-37.
26. Kamen BA, Wang MT, Streckfuss AJ, Peryea X, Anderson RG. Delivery of folates to the cytoplasm of MA104 cells is mediated by a surface membrane receptor that recycles. J Biol Chem 1988;263:13602-9.
27. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
28. Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 2004;96:134-44.
29. Peters GJ, Wets M, Keepers YP, et al. Transformation of mouse fibroblasts with the oncogenes H-ras OR trk is associated with pronounced changes in drug sensitivity and metabolism. Int J Cancer 1993;54:450-5.
30. Draper NR, Smith H. Applied regression analysis. 2nd ed. New York: John Wiley & Sons; 1981.
31. Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 2007;6:404-17.
32. Lin JT, Bertino JR. Update on trimetrexate, a folate antagonist with antineoplastic and antiprotozoal properties. Cancer Invest 1991;9:159-72.
33. Liu Y, Raghunathan K, Hill C, et al. Effects of antisense-based folypoly-γ-glutamate synthetase down-regulation on reduced folates and cellular proliferation in CCRF-CEM cells. Biochem Pharmacol 1998;55:2031-7.
34. Chazal M, Cheradame S, Formento JL, et al. Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracil-folinic acid treatment: clinical data. Clin Cancer Res 1997;3:553-7.
35. Mini E, Biondi C, Morganti M, et al. Marked variation of thymidylate synthase and folylpolyglutamate synthetase gene expression in human colorectal tumors. Oncol Res 1999;11:437-45.
36. Odin E, Wettergren Y, Nilsson S, et al. Altered gene expression of folate enzymes in adjacent mucosa is associated with outcome of colorectal cancer patients. Clin Cancer Res 2003;9:6012-9.
37. Jansen G, Peters GJ, Pinedo HM, Priest DG, Assaraf YG. Re: Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo. J Natl Cancer Inst 1999;91:2047-50.
38. Jansen G, Barr H, Kathmann I, et al. Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation, expanded folate pools, and intralysosomal drug sequestration. Mol Pharmacol 1999;55:761-9.
39. Jansen G, Mauritz R, Drori S, et al. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem 1998;273:30189-98.
40. Peters GJ, Smitskamp-Wilms E, Smid K, Pinedo HM, Jansen G. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions. Cancer Res 1999;59:5529-35.
41. Tse A, Moran RG. Cellular folates prevent polyglutamation of 5, 10-dideazatetrahydrofolate. A novel mechanism of resistance to folate antimetabolites. J Biol Chem 1998;273:25944-52.
42. O'Dwyer PJ, Nelson K, Thornton DE. Overview of phase II trials of MTA in solid tumors. Semin Oncol 1999;26:99-104.
43. Colozza M, de Azambuja E, Cardoso F, Bernard C, Piccart MJ. Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era. The Oncologist 2006;11:111-25.